BR9712368A - Gene clk-1, mouse model of longevity and processes for diagnosis and / or prognosis of cancer in a patient, to increase the life span of an animal or a patient, and to treat pathological conditions that cause the reduction the rhythm of the physiological rate of tissue and / or organ in a patient. - Google Patents

Gene clk-1, mouse model of longevity and processes for diagnosis and / or prognosis of cancer in a patient, to increase the life span of an animal or a patient, and to treat pathological conditions that cause the reduction the rhythm of the physiological rate of tissue and / or organ in a patient.

Info

Publication number
BR9712368A
BR9712368A BR9712368-4A BR9712368A BR9712368A BR 9712368 A BR9712368 A BR 9712368A BR 9712368 A BR9712368 A BR 9712368A BR 9712368 A BR9712368 A BR 9712368A
Authority
BR
Brazil
Prior art keywords
patient
cancer
clk
tissue
pathological conditions
Prior art date
Application number
BR9712368-4A
Other languages
Portuguese (pt)
Inventor
Siegfried Hekimi
Thomas Barnes
Bernard Lakowski
Jonathan Ewbank
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Publication of BR9712368A publication Critical patent/BR9712368A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0335—Genetically modified worms
    • A01K67/0336—Genetically modified Nematodes, e.g. Caenorhabditis elegans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"GENE CLK-1, MODELO DE CAMUNDONGO DE LONGEVIDADE E PROCESSOS PARA DIAGNóSTICO E/OU PROGNóSTICO DE CâNCER EM UM PACIENTE, PARA AUMENTO DO ESPAçO DE TEMPO DE VIDA DE UM ANIMAL OU UM PACIENTE, E, PARA TRATAMENTO DE CONDIçõES PATOLóGICAS QUE PROVOCAM A REDUçãO DO RITMO DA TAXA FISIOLóGICA DE TECIDO E/OU óRGãO EM UM PACIENTE". A presente invenção refere-se a um gene clk-1 que tem uma função no nível de fisiologia celular envolvida na taxa de desenvolvimento e longevidade, em que os mutantes clk-1 tem uma vida mais longa e um metabolismo celular alterado com relação ao tipo selvagem. Também é provido um processo para o diagnóstico e/ou prognóstico de câncer em um paciente, que compreende as etapas de a) obter uma amostra de tecido do paciente, b) analisar DNA da amostra de tecido obtida da etapa a) para determinar se o gene clk-1 humano é alterado, em que a alteração do gene clk-1 humano é indicativa de câncer. Também é provido um processo de tratamento de condições patológicas provocando a redução do ritmo da taxa fisiológica de tecido e/ou órgão em um paciente."GENE CLK-1, MOUNTAIN MODEL OF LONGEVITY AND PROCESSES FOR DIAGNOSIS AND / OR PROGNOSIS OF CANCER IN A PATIENT, FOR INCREASING THE LIFE SPACE OF AN ANIMAL OR A PATIENT, AND, FOR TREATMENT OF PATHOLOGICAL CONDITIONS THAT PROVIDE PATHOLOGICAL CONDITIONS THAT PROVIDE REDUCING THE RHYTHM OF THE PHYSIOLOGICAL RATE OF TISSUE AND / OR ORGAN IN A PATIENT ". The present invention relates to a clk-1 gene that has a function at the level of cell physiology involved in the rate of development and longevity, in which clk-1 mutants have a longer life and altered cell metabolism with respect to the type wild. A process for the diagnosis and / or prognosis of cancer in a patient is also provided, comprising the steps of a) obtaining a tissue sample from the patient, b) analyzing DNA from the tissue sample obtained from step a) to determine whether the human clk-1 gene is altered, in which the alteration of the human clk-1 gene is indicative of cancer. A process for treating pathological conditions is also provided, causing a reduction in the rhythm of the physiological rate of tissue and / or organ in a patient.

BR9712368-4A 1996-10-21 1997-10-17 Gene clk-1, mouse model of longevity and processes for diagnosis and / or prognosis of cancer in a patient, to increase the life span of an animal or a patient, and to treat pathological conditions that cause the reduction the rhythm of the physiological rate of tissue and / or organ in a patient. BR9712368A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2897796P 1996-10-21 1996-10-21
US3319696P 1996-12-18 1996-12-18
PCT/CA1997/000768 WO1998017823A1 (en) 1996-10-21 1997-10-17 STRUCTURAL AND FUNCTIONAL CONSERVATION OF THE C. ELEGANS CLOCK GENE $i(clk-1)

Publications (1)

Publication Number Publication Date
BR9712368A true BR9712368A (en) 2000-01-25

Family

ID=26704340

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712368-4A BR9712368A (en) 1996-10-21 1997-10-17 Gene clk-1, mouse model of longevity and processes for diagnosis and / or prognosis of cancer in a patient, to increase the life span of an animal or a patient, and to treat pathological conditions that cause the reduction the rhythm of the physiological rate of tissue and / or organ in a patient.

Country Status (9)

Country Link
EP (1) EP0932701A1 (en)
JP (1) JP2001502181A (en)
KR (1) KR20000052654A (en)
CN (1) CN1234077A (en)
AU (1) AU743527B2 (en)
BR (1) BR9712368A (en)
CA (1) CA2268749A1 (en)
NZ (1) NZ335335A (en)
WO (1) WO1998017823A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058671A2 (en) * 1998-05-08 1999-11-18 Research Corporation Technologies, Inc. Human and nematode homologues of the yeast longevity assurance gene lag1
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
EP1325124A2 (en) * 2000-06-22 2003-07-09 McGILL UNIVERSITY Clk-2, cex-7 and coq-4 genes, and uses thereof
US7572575B2 (en) 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
CN103088021B (en) * 2011-10-31 2015-08-05 中国科学院动物研究所 MiR-45 regulates and controls application and the method in nematode life-span
FR3012739A1 (en) 2013-11-07 2015-05-08 Centre Nat Rech Scient SNO RNA, COMPOSITIONS AND USES
JP7186457B2 (en) * 2019-08-01 2022-12-09 国立大学法人 熊本大学 Evaluation system for healthy life expectancy at the individual level using nematodes

Also Published As

Publication number Publication date
JP2001502181A (en) 2001-02-20
WO1998017823A1 (en) 1998-04-30
CA2268749A1 (en) 1998-04-30
KR20000052654A (en) 2000-08-25
NZ335335A (en) 2000-11-24
CN1234077A (en) 1999-11-03
AU4612897A (en) 1998-05-15
EP0932701A1 (en) 1999-08-04
AU743527B2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
Davis et al. Stress-induced activation of prefrontal cortex dopamine turnover: blockade by lesions of the amygdala
Greer et al. Towards a psychobiological model of cancer: psychological considerations
Riccardi Pathophysiology of neurofibromatosis: IV. Dermatologic insights into heterogeneity and pathogenesis
Gordon et al. Improving survival in a large French ALS center cohort
BR9712368A (en) Gene clk-1, mouse model of longevity and processes for diagnosis and / or prognosis of cancer in a patient, to increase the life span of an animal or a patient, and to treat pathological conditions that cause the reduction the rhythm of the physiological rate of tissue and / or organ in a patient.
Cosseddu et al. Sex and side differences in the minor non-metrical cranial variants
Segal et al. Increase in Ca2+-activated cAMP/PKA signaling prevents hydroxychloroquine-induced bradycardia of the cardiac pacemaker
CN115261355B (en) AMPK alpha 1 succinylation modification and application
Saumarez et al. Delayed paced ventricular activation in the long QT syndrome is associated with ventricular fibrillation
Effendi Reconstruction of the middle-aged torn earlobe: a new method
Hanson Population‐specific stature reconstruction for medieval Trondheim, Norway
Kubota et al. Skin manifestations of a patient with mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS syndrome)
Panwar et al. Existence and Uniqueness of Solutions for Mixed Immunotherapy and Chemotherapy Cancer Treatment Fractional Model with Caputo-Fabrizio Derivative
Gambardella et al. Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths (CMT4B)
Struk et al. Vegetative and endocrine predictors of individual immune responses to adaptogenic balneotherapy
Martensen Cancer: medical history and the framing of a disease
Hemmrich et al. Unusual Bilateral Distribution of Neurofibromatosis Type 5 on the Distal Upper Extremities
Watine Defining laboratory medicine, or squaring the circle?
Stotts et al. Congenital, segmental pigmented lesions
Sehgal et al. Lymphocyte adenosine deaminase activity (L‐ADA) in leprosy, during and after treatment of reactions
Ahn et al. Sex determination through metric analysis of teeth crown
Jasim et al. Assessment of Serum Vit D and Serum Ferritin in Female Pattern Androgenic Alopecia.
Korhonen Learning disabilities in children. An empirical subgrouping and follow-up.
BR0209287A (en) Methods for profiling gene, protein or melabolite expression levels
Smith Methylation Patterns Across Tissue Type and Time in Peromyscus leucopus: A Targeted Museum Study

Legal Events

Date Code Title Description
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements